GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nkarta Inc.
Shares of Nkarta, a biotech company developing NK cell-based cell therapy, are a venture bet on a new approach to cancer treatment. Their price is highly volatile and driven by news of clinical trials.
Share prices of companies in the market segment - Cancer blood
Nkarta, Inc. is a biotechnology company developing natural killer (NK) cell-based therapies for the treatment of oncological diseases, primarily hematological ones. We classify it as a "Blood Cancer Treatment" company, where cell therapy is a breakthrough. The chart below shows the dynamics of this innovative sector.
Broad Market Index - GURU.Markets
Nkarta is a biotech company developing universal ("allogeneic") cell therapy based on natural killer (NK) cells for the treatment of cancer. Its cutting-edge approach makes it a component of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
NKTX - Daily change in the company's share price Nkarta Inc.
For Nkarta, Inc., a cell therapy company, daily price change is a measure of extreme volatility. It reflects the market's reaction to research data and is a critical parameter in the risk assessment formulas for innovative biotech companies on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Cancer blood
Nkarta, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the performance of NKTX, a pioneer in cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Nkarta is a biotech company developing cutting-edge cell therapies for cancer treatment. Its shares live to the rhythm of scientific discoveries and clinical data. This high, event-driven volatility feeds into the overall market flow, making the picture more complex and multifaceted.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nkarta Inc.
For Nkarta, Inc., the year-over-year trend is a story about developing a "ready-to-use" cell therapy based on natural killer (NK) cells. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its approach could offer a safer and more affordable alternative to complex CAR-T therapies.
Annual dynamics of market capitalization of the market segment - Cancer blood
Nkarta, Inc. is a biotech company developing off-the-shelf NK cell-based therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its innovative platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nkarta is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nkarta Inc.
Nkarta develops cell therapy (NK cells) for cancer treatment. Its monthly price movement is entirely tied to scientific progress. News from medical conferences, clinical trial data, and technological breakthroughs in cell production are the only significant drivers causing sharp movements on the chart.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Nkarta is a biotech company developing natural killer (NK) cell-based cell therapy for cancer treatment. It is a promising alternative to CAR-T therapy. The graph below illustrates the overall dynamics in the cell therapy sector, where new, safer, and more effective approaches are being actively explored.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working at the cutting edge of science, such as cell therapy, often move independently of the market. The chart below shows the overall sentiment. Does Nkarta, Inc. live in a world of its own, where development news trumps overall market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nkarta Inc.
Shares of Nkarta, a company developing "off-the-shelf" cell therapies for cancer treatment, reflect progress in this cutting-edge field every week. The price movement is a response to clinical data that may demonstrate the superiority of their approach over more complex and personalized methods.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Nkarta is developing cell therapy for blood cancer using natural killer (NK) cells. This is a promising area of oncology. The chart will show whether NKTX's weekly share price fluctuations reflect its unique research results or reflect overall investor sentiment toward the entire cell therapy sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Nkarta is a biotech company working in the cutting-edge field of cell therapy. Shares of such innovative companies often move independently of the market. This chart will help you understand: does Nkarta live in its own world of clinical trials, or are overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
NKTX - Market capitalization of the company Nkarta Inc.
Nkarta's market capitalization tells the story of a biotech company developing natural killer (NK) cell-based therapies for cancer. Its volatile price chart reflects its hopes for ready-to-use cell-based therapies. Its performance reflects the market's appreciation of its scientific platform and early clinical trial data.
NKTX - Share of the company's market capitalization Nkarta Inc. within the market segment - Cancer blood
Nkarta is a biotech company developing ready-to-use cell therapies based on natural killer (NK) cells for cancer treatment. Its market cap reflects the potential of this approach, which could make cell therapy more accessible. The chart below shows the market's appetite for this oncology innovation.
Market capitalization of the market segment - Cancer blood
Nkarta is a biotech company at the forefront of developing NK cell therapies for cancer treatment. The chart below shows the market capitalization of this innovative sector. Its volatility reflects both the enormous hopes for a breakthrough in oncology and the risks associated with clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
Nkarta is a biotech company working in the field of cancer therapy using natural killer (NK) cells. Its market cap reflects the bet that this approach will become a powerful new weapon against cancer. Its performance on the overall chart reflects progress at the forefront of cell therapy.
Book value capitalization of the company, segment and market as a whole
NKTX - Book value capitalization of the company Nkarta Inc.
Nkarta's book value is its capital and production capacity, which are focused on developing "off-the-shelf" cell therapy (NK cells) for cancer treatment. This is the tangible, scientific foundation for creating universal and affordable cell-based medicines. How has this capital-intensive asset changed? The chart below shows its dynamics.
NKTX - Share of the company's book capitalization Nkarta Inc. within the market segment - Cancer blood
Nkarta develops NK cell-based therapies for cancer treatment, which requires advanced cleanrooms and laboratories. The chart shows the share of these unique tangible assets in the biotech sector, reflecting the physical foundation of its cell therapy.
Market segment balance sheet capitalization - Cancer blood
Nkarta is developing cell therapy for cancer treatment. This cutting-edge science doesn't require massive factories at the R&D stage. The book value chart will show how "light" the company's capital base is, with the potential hidden in its technologies.
Book value of all companies included in the broad market index - GURU.Markets
Nkarta, Inc. is a pioneer in the development of "off-the-shelf" cancer cell therapies. Its book value is derived from its advanced NK cell production facilities, laboratories, and R&D centers. The chart shows the physical scale of the infrastructure required for the mass production of living drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nkarta Inc.
Nkarta's balance sheet consists of capital and laboratories. But the market sees it as a pioneer in "off-the-shelf" cell therapy. The chart shows a colossal "hope factor": a premium on its potential to create a universal cancer cure that doesn't require individualized treatment for each patient.
Market to book capitalization ratio in a market segment - Cancer blood
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. The chart shows how highly investors value the potential of this cutting-edge cell therapy, betting on the future success of its clinical programs.
Market to book capitalization ratio for the market as a whole
Nkarta, Inc. is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. Its approach is to create "ready-to-use" cell therapies. This chart shows the overall valuation, but how does the market value a company that aims to make cell therapy accessible and affordable?
Debts of the company, segment and market as a whole
NKTX - Company debts Nkarta Inc.
Nkarta, a cell therapy company, is spending heavily on its cutting-edge research. This chart shows how it is raising capital to fund its unique platform of "off-the-shelf" NK cells. This investment is aimed at creating a new generation of cancer treatments that can be made accessible to a wide range of patients.
Market segment debts - Cancer blood
Nkarta is developing natural killer (NK) cell-based therapies for the treatment of cancer. This is a cutting-edge and highly competitive approach to cell therapy. This chart shows how the company is raising the significant capital needed to fund its complex and expensive clinical programs in this innovative field.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nkarta Inc.
Nkarta is developing cutting-edge NK cell-based treatments for blood cancer. This chart shows how the biotech company is funding its revolutionary, yet extremely expensive, research. The level of debt here represents the stakes placed on the success of its scientific platform, which could either yield a colossal return or wipe out the investment.
Market segment debt to market segment book capitalization - Cancer blood
Nkarta is developing natural killer (NK) cell-based therapies for cancer treatment. This chart illustrates the financial leverage in the cutting-edge cell therapy sector. It provides insight into how the industry as a whole finances its capital-intensive research and development and the development of manufacturing facilities, and how Nkarta's strategy compares to this trend.
Debt to book value of all companies in the market
Nkarta, Inc. is a biotech company developing cell therapies for cancer treatment. R&D funding relies almost entirely on equity. This chart, reflecting general debt trends, highlights that the biotech world operates by its own rules, where risks and capital sources differ radically from those of traditional economics.
P/E of the company, segment and market as a whole
P/E - Nkarta Inc.
This chart for Nkarta, Inc., a company developing NK cell-based cell therapy, shows investor expectations. Its value reflects not current profits, but rather the belief in the potential of its "off-the-shelf" cancer treatment platform. It's an estimate of a future breakthrough in oncology that could make therapy more accessible than existing methods.
P/E of the market segment - Cancer blood
The cancer cell therapy being developed by Nkarta is personalized medicine. This chart shows the average rating for biopharmaceutical companies. It helps to understand that Nkarta, with its "ready-to-use" NK cell technology, is being evaluated based on the potential of this approach, which may be simpler and less expensive than other cell therapies.
P/E of the market as a whole
Nkarta, Inc. is developing natural killer (NK) cell-based therapy for cancer treatment. This is a promising approach to cellular immunotherapy that may be more affordable than CAR-T. This chart, reflecting investor risk appetite, shows how willing the market is to invest in this cutting-edge, yet experimental, technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nkarta Inc.
Nkarta is a biotech company developing natural killer (NK) cell-based cell therapies for cancer treatment. This chart reflects speculative expectations for its innovative platform. The dynamics reflect the market's assessment of scientific progress and the potential for creating "ready-to-use" cell therapies.
%20P%2FE%20Nkarta%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nkarta-Inc.&v=1772629796208 "Chart of the company's future (projected) P/E Nkarta Inc.")
Future (projected) P/E of the market segment - Cancer blood
Nkarta develops natural killer (NK) cell-based therapies for cancer treatment. This chart shows profitability expectations for the cell therapy sector. It provides insight into how highly the market values the potential of off-the-shelf (allogeneic) NK cells as a more affordable alternative to personalized CAR-T cells.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772629796215 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Nkarta, Inc. is a biopharmaceutical company developing natural killer (NK) cell-based therapies for cancer treatment. This chart shows investors' risk appetite. For a company at the forefront of cellular immunotherapy, it reflects the market's willingness to fund innovative approaches that have not yet been widely proven effective.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772629796216 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nkarta Inc.
Nkarta, Inc. is a biotechnology company developing ready-to-use natural killer (NK) cell-based therapies for cancer treatment. The financial outcome illustrated in this chart is comprised of research and clinical trial costs. It reflects the cost of developing innovative, "standard" cell therapies.
Profit of companies in the market segment - Cancer blood
Nkarta is a biopharmaceutical company developing "ready-to-use" (allogeneic) cell therapies based on natural killer (NK) cells for the treatment of cancer. This approach has the potential to make cell therapy more accessible. This chart illustrates how innovations in cell engineering can revolutionize oncology and determine the future profitability of this sector.
Overall market profit
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This is at the cutting edge of science. For companies like Nkarta, the overall economic climate, reflected in this chart, is important in terms of the availability of venture capital and the willingness of major pharma companies to partner and acquire.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nkarta Inc.
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. The earnings forecast on this chart reflects analysts' expectations for clinical trials. This is a bet that its platform for creating "off-the-shelf" cell therapies will be successful.
%20profit%20of%20the%20company%20Nkarta%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nkarta-Inc.&v=1772629796249 "Graph of future (projected) profit of the company Nkarta Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
Nkarta, Inc. develops natural killer cell (NK)-based therapies for the treatment of cancer, particularly hematological malignancies. This is a cutting-edge approach in cell therapy. This chart shows the revenue forecast for the blood cancer sector, providing insight into how the market views the potential of Nkarta's NK cell platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772629796251 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Nkarta is a biotech company developing NK cell-based cell therapy for cancer treatment. Its future depends on the success of clinical trials. This chart, reflecting market sentiment, influences investor willingness to invest in capital-intensive and risky projects in advanced medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772629796253 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nkarta Inc.
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This chart shows a speculative estimate of its future potential. This estimate is a bet that its innovative approach to cell therapy will prove effective and safe.
P/S market segment - Cancer blood
Nkarta, Inc. is a biotech company developing cancer therapies based on allogeneic natural killer (NK) cells derived from healthy donors. This chart reflects investor expectations for this cutting-edge technology. It shows the premium the market is willing to pay for the potential to create a universal cell-based cancer treatment.
P/S of the market as a whole
Nkarta is a biopharmaceutical company developing natural killer (NK) cell-based therapies for cancer treatment. This is a cutting-edge approach to cellular immunotherapy. This chart helps understand how the market values companies at the forefront of science, whose potential revenues can be enormous but require significant investment and time.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nkarta Inc.
Nkarta develops natural killer (NK) cell-based therapies for the treatment of cancer. This chart shows the company's valuation relative to its future, hypothetical, sales. It reflects investors' confidence in the potential of its off-the-shelf cell therapy and the success of its clinical programs.
%20P%2FS%20Nkarta%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nkarta-Inc.&v=1772629796271 "The graph of the company's future (projected) P/S Nkarta Inc.")
Future (projected) P/S of the market segment - Cancer blood
Nkarta develops natural killer (NK) cell-based cell therapy for the treatment of cancer, primarily hematological malignancies. This is an innovative approach in immuno-oncology. This chart shows investor expectations for its scientific platform and future revenue compared to other cell therapy companies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772629796272 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. Its future depends on the success of clinical trials. This general expectations chart for NKTX is not a direct driver. The company's value is determined by its scientific potential, not short-term economic trends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772629796274 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nkarta Inc.
This chart illustrates the financial trajectory of a biotech company. For Nkarta, which develops natural killer (NK) cell-based therapies, it reflects the revenue from collaborations and funding needed to advance its innovative cancer treatments through clinical trials.
Sales of companies in the market segment - Cancer blood
Nkarta, Inc. is developing natural killer (NK) cell-based therapies for the treatment of cancer. This innovative approach has the potential to offer a ready-to-use cell therapy. This graph reflects revenue in oncology, and commercialization of Nkarta's technology has the potential to create a new standard in cell therapy and significantly expand the market.
Overall market sales
Nkarta is a biotechnology company developing natural killer (NK) cell-based therapies for cancer treatment. This is one of the most advanced approaches in cell therapy. Nkarta's success depends on scientific innovation and reflects how fundamental science can lead to new markets and treatments in the future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nkarta Inc.
Nkarta develops natural killer (NK) cell-based therapies for the treatment of oncological diseases, primarily blood cancers. Future sales projections depend on the success of its cutting-edge clinical trials. This timeline reflects hopes for a breakthrough in cellular immunotherapy.
%20sales%20of%20the%20company%20Nkarta%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nkarta-Inc.&v=1772629796404 "Schedule of future (projected) sales of the company Nkarta Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
Nkarta, Inc. develops natural killer (NK) cell-based therapies for cancer treatment. This forecast for the blood cancer and cell therapy sector highlights the expected innovations. The chart highlights the potential for off-the-shelf cell therapies, which could become more accessible than personalized therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772629796424 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Nkarta is a biotech company developing natural killer (NK) cell therapy for cancer treatment. Its future success depends on the results of clinical trials. The overall economic situation, reflected in this chart, does not affect the demand for treatment, but it may influence investors' overall appetite for risky assets in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772629796433 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nkarta Inc.
Nkarta, Inc. is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. While in clinical trials, it incurs significant R&D expenditures. This chart illustrates the investment in its cutting-edge scientific platform, which represents the cost of developing potentially breakthrough treatments.
Market segment marginality - Cancer blood
Nkarta, Inc. is a biotechnology company developing natural killer (NK) cell-based therapies for the treatment of cancer. Profitability is a future goal, contingent on the success of clinical trials. This metric reflects Nkarta's operational structure and the intensity of its investment in advanced cell therapies compared to other oncology companies.
Market marginality as a whole
Nkarta, Inc. is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This chart shows total revenue. Against this backdrop, Nkarta is a story of an innovative approach in immuno-oncology. The company is not profitable, and its market cap reflects the company's expectations for the success of its scientific platform.
Employees in the company, segment and market as a whole
Number of employees in the company Nkarta Inc.
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for the treatment of cancer. Its team consists primarily of scientists and cell manufacturing specialists. The growth in this chart directly reflects investment in its platform and the progress of its cell product candidates through clinical trials.
Share of the company's employees Nkarta Inc. within the market segment - Cancer blood
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This chart demonstrates its leadership in this innovative niche. It reflects the significant proportion of leading immunologist and cell engineering specialists working on this cutting-edge technology that Nkarta has on its team.
Number of employees in the market segment - Cancer blood
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This chart illustrates cutting-edge research in cell therapy. The growing number of scientists here demonstrates progress in creating "off-the-shelf" cell therapies, which could be more affordable than personalized CAR-T therapies.
Number of employees in the market as a whole
Nkarta, Inc. is a biotech company developing cell therapies for cancer treatment. Their development is entirely dependent on scientific breakthroughs and funding. This overall workload schedule is irrelevant to them. Success in clinical trials could attract investment, allowing them to significantly expand their team of top scientists in their field.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nkarta Inc. (NKTX)
Nkarta, Inc. is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. They are at the forefront of cellular immunotherapy. This chart demonstrates how the market values this scientific breakthrough. The astronomical market capitalization per employee reflects not current revenue, but the enormous potential of their platform for creating ready-to-use cell-based therapies.
%20of%20the%20company%20Nkarta%20Inc.%20(NKTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nkarta-Inc.-NKTX&v=1772629796568 "Chart of market capitalization per employee (in thousands of dollars) of the company Nkarta Inc. (NKTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Nkarta develops NK cell-based cancer treatments. This is a complex and cutting-edge field of biotechnology. The company's value is determined by its scientific platform and clinical trial results. This chart illustrates the enormous premium the market places on the intellectual contribution of each scientist working on the development of a new generation of drugs.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772629796580 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Nkarta develops natural killer (NK) cell-based therapies for cancer treatment. This is at the forefront of cell therapy. This graph demonstrates the employee's high rating, as its innovative platform can create "off-the-shelf" cell therapies, a Holy Grail for this industry.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772629796582 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nkarta Inc. (NKTX)
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This is a cutting-edge cellular immunotherapy. This indicator is negative. It reflects the enormous cost of R&D. It shows how much the company invests in each highly qualified scientist to create and test these "living" drugs.
%20Chart%20Nkarta%20Inc.%20(NKTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nkarta-Inc.-NKTX&v=1772629796590 "Company Profit Per Employee (in thousands of dollars) Chart Nkarta Inc. (NKTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Nkarta (NKTX) is a biotech company developing cell therapy (CAR-NK) for cancer treatment. Like other R&D companies in this space, this chart represents a future target, not a current reality. Currently, profitability is negative. Success for NKTX would mean that their research team has created a product that will transform medicine and provide a tremendous return on investment.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772629796623 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Nkarta (NKTX) is a biotech company developing cell therapy (NK cells) for cancer treatment. This is at the cutting edge of science. The company is in the R&D stage, and its profit per employee is deeply negative. This reflects only the scale of its investment in the team of scientists working to create the "living" drugs of the future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772629796645 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nkarta Inc. (NKTX)
Nkarta is developing natural killer (NK) cell-based therapies for cancer treatment. This chart reflects its clinical-stage status. No revenue is normal. This metric serves as a benchmark that, if commercially successful, will demonstrate the enormous value created by its scientific team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nkarta-Inc.-NKTX&v=1772629796647 "Sales chart per company employee Nkarta Inc. (NKTX)")
Sales per employee in the market segment - Cancer blood
Nkarta, Inc. is a biotech company specializing in the development of "off-the-shelf" (allogeneic) cell therapies (NK cells) for cancer treatment. At the R&D stage, this metric reflects how effectively their scientific team generates revenue (e.g., from partnerships) per employee, which is critical to funding their complex platform.
Sales per employee for the market as a whole
Nkarta is a clinical-stage biotech company developing CAR-NK cell therapy for cancer. It is a 100% R&D company. This chart shows revenue per employee. Predictably, it is zero. It emphasizes that the company doesn't sell products, but rather invests in lengthy and expensive clinical trials, where its scientific staff creates future value.
Short shares by company, segment and market as a whole
Shares shorted by company Nkarta Inc. (NKTX)
Nkarta, Inc. is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. This is a cutting-edge but high-risk approach. This chart shows bearish bets. Bears are betting that clinical trials will not confirm the safety or efficacy of this cell therapy, or that its production will be too complex.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nkarta-Inc.-NKTX&v=1772629796684 "Short Shares Chart for the Company Nkarta Inc. (NKTX)")
Shares shorted by market segment - Cancer blood
Nkarta is a biotech company specializing in developing natural killer (NK) cell-based therapies for cancer treatment. This chart shows overall short positions in the cell therapy sector. High values reflect investor doubts about the technology across the industry, anticipating production issues or the effectiveness of such complex treatments.
Shares shorted by the overall market
Nkarta (NKTX) is a clinical-stage biotech company working in cell therapy. Its value reflects the hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nkarta Inc. (NKTX)
Nkarta is a biotech company focused on NK cell therapy. Its shares are highly volatile and dependent on R&D. This chart can surge above 70 on positive trial data or partnerships. Oversold levels (<30) are often associated with setbacks, delays, or a general downturn in biotech, causing investor panic.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nkarta-Inc.-NKTX&v=1772629796707 "RSI 14 indicator chart for the company's stock Nkarta Inc. (NKTX)")
RSI 14 Market Segment - Cancer blood
Nkarta (NKTX) is "CAR-T" 2.0. They're "engineering" *NK-cells* (natural killer cells)—creating a "universal" (off-the-shelf) cure for blood cancer. RSI_14_Seg for "Cancer Blood" (biotech) shows the overall sentiment. It helps us understand: is NKTX's volatility due to their R&D, or is the *entire* sector "overheated"?
RSI 14 for the overall market
Nkarta (NKTX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NKTX (Nkarta Inc.)
Nkarta is a biotech company developing natural killer (NK) cell-based therapies for cancer treatment. It's an off-the-shelf cell therapy. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this cutting-edge immuno-oncology platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NKTX-Nkarta-Inc.&v=1772629796727 "A chart showing analyst consensus forecasts for the expected stock price. NKTX (Nkarta Inc.)")
The difference between the consensus estimate and the actual stock price NKTX (Nkarta Inc.)
Nkarta (NKTX) is a biotech company developing "allogeneic" (donor-derived, "off-the-shelf") NK cell therapy for blood cancer. This R&D bet is on a breakthrough. This chart shows the "hope gap." It measures the difference between the price and the consensus target, reflecting the enormous potential analysts see in their "universal" cell therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NKTX-Nkarta-Inc.&v=1772629796736 "A chart showing the difference between the consensus forecast and the actual stock price. NKTX (Nkarta Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Nkarta (NKTX) is a biotech company developing a "universal" cell therapy based on natural killer (NK) cells for cancer treatment. This chart shows analysts' overall expectations for the blood oncology sector. It reflects whether experts believe in a breakthrough in "off-the-shelf" cell therapies.
Analysts' consensus forecast for the overall market share price
Nkarta (NKTX) is a biotech company developing "off-the-shelf" (allogeneic) NK cell therapies for cancer treatment. This is "test tube cell therapy." This chart shows the overall risk appetite. For Nkarta, operating in one of the most advanced and expensive areas of medicine, overall market optimism is critical to attracting the capital needed to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nkarta Inc.
Nkarta is a biotech company working in the hot field of cell therapy. Their specialty is NK (natural killer) cells: they are developing a universal (allogeneic) cell therapy for blood cancer that requires no personalization. This chart is a clear indicator of their belief in their cutting-edge science. It reflects their progress in clinical trials and their race with CAR-T therapies.
AKIMA Market Segment Index - Cancer blood
Nkarta is a biotech company developing off-the-shelf (allogeneic) cell therapies based on natural killer (NK) cells for the treatment of blood cancers. This chart shows the average index for the blood cancer sector. It provides investors with a benchmark for how Nkarta's performance, with its breakthrough technology, compares to the sector average.
The AKIM Index for the overall market
Nkarta is a biotech company developing allogeneic ("off-the-shelf") NK cell-based therapies for cancer treatment. This chart, reflecting the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this cutting-edge and capital-intensive scientific platform.
